GET DAILY SIGNALSWhy Is Sutro Biopharma (STRO) Stock Down -7.39% Today?
Key Takeaways
- Sutro Biopharma (STRO) shares were down about 7.39% in intraday trading, trading near $9.53 versus a prior close of $10.29.
- The decline reflects continued selling pressure in a stock that has already fallen sharply over the past month, with no single company-specific announcement driving today's move.
- Lingering investor concerns over the progress of the lead STRO-004 Phase 1 program, following a mixed early data update, remain a key overhang.
- The slide extends a broader downtrend for clinical-stage oncology names, with the stock trading well below its 50-day and 200-day moving averages.
- Traders are watching whether shares can hold the $10 psychological level and for the next earnings report, expected in early November.
- For additional details on Price Targets, Earnings, and Forecast data, explore the dedicated pages on Tickeron.
- Discover how AI-driven strategies are trading this and other tickers by exploring Trending AI Robots.
Opening Summary
Sutro Biopharma, Inc. (STRO) is a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) for cancer, built around its proprietary cell-free protein synthesis platform. In today's session, the stock extended its recent decline, falling roughly 7.39% to trade near $9.53, compared with a prior close of $10.29. The move pushed shares below the closely watched $10 level and came without a fresh, single catalyst, suggesting the weakness reflects persistent negative sentiment and ongoing technical selling rather than a discrete new development.
Lingering Pressure on the STRO-004 Program
The most significant overhang on STRO traces back to the company's second-quarter update, when early Phase 1 data for its lead tissue factor-targeting ADC, STRO-004, revealed challenges that disappointed investors. Although the update pointed to some confirmed and unconfirmed partial responses, the market has remained skeptical about the pace and durability of the program's progress. That skepticism has kept a lid on the stock and contributed to repeated bouts of selling as traders reassess the risk profile of the lead asset.
Profit-Taking After Pipeline Announcements
Earlier this week, STRO announced it had dosed the first patient in a Phase 1 trial of STRO-006, its next-generation ITGB6-targeting ADC. While pipeline progress is generally viewed as a positive, the market has treated such updates with a "sell-the-news" mentality amid the stock's broader downtrend. With initial clinical data for STRO-006 not expected until the second half of 2027, near-term catalysts remain limited, leaving the shares vulnerable to profit-taking and momentum-driven selling.
Market Context and Trading Activity
The decline in STRO is part of a pronounced technical breakdown. The stock has lost roughly 36% over the past month and more than 55% over the past three months, and it now trades well below its 50-day and 200-day moving averages. Momentum indicators have signaled oversold conditions, yet buyers have failed to step in with conviction. The breach below the $10 round-number level today added to the bearish tone, and the move occurred against a backdrop of tepid risk appetite for small-cap and clinical-stage biotech names, which have underperformed broader market averages in recent weeks.
What Comes Next for STRO
Looking ahead, investors will focus on STRO's next quarterly earnings report, which is expected in early November, for updates on the STRO-004 program, cash runway, and any strategic adjustments. Key uncertainties include the durability of early responses in the lead program, the timeline for additional clinical data, and the company's funding position for advancing its broader pipeline. While analyst sentiment has remained broadly constructive relative to the current share price, the disconnect between high price targets and the stock's depressed level underscores the market's near-term caution. Risks include further clinical setbacks, dilution, and continued weakness across the biotech sector.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are currently among the strongest performers in live market conditions. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the top-performing strategies are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to observe how data-driven systems are navigating volatile names like STRO. Explore the page to see which AI strategies are gaining traction today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STRO in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
STRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 49 cases where STRO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where STRO advanced for three days, in 209 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STRO as a result. In 73 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for STRO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for STRO moved below the 200-day moving average on September 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STRO entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.651) is normal, around the industry mean (2.973). P/E Ratio (-0.592) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (3.982) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. STRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of new products in protein vaccines and therapeutics
Industry Biotechnology
Advertisement